Company is Well Positioned to Continue to Compete and GrowMARIETTA, Ga., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of the CY 2026 Physician Fee Schedule (“PFS”) final rule, which was published on Friday. “Over the last several years, we have actively engaged with numerous stakeholders to advocate for much-needed reform of the Medicare reimbursement system for skin substitut ...

UTime Limited UTime Limited Explores Application of AI Technology in Health Data Analysis UTime Limited The company is developing AI-based algorithm models SHENZHEN, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- UTime Limited (Nasdaq: WTO) today outlined its ongoing exploration in the field of health data analysis, particularly the potential application of artificial intelligence (AI) technologies. UTime is developing AI-based algorithm models aimed at performing in-depth analysis of continuous physiol ...

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS) in the dose escalation cohort HOUSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies fo ...

Trust Stamp announces a Cryptocurrency Initiative including the TSI Wallet™, a biometrically secured digital asset wallet that will both compete with and compliment legacy wallets in the crypto wallet market which is predicted to grow from $14.39B in 2024 to $54.79B in 2029Atlanta, GA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Trust Stamp (Nasdaq: IDAI): In the wake of recent announcements that the Company has raised in excess of $10M in new capital, the Company announced a cryptocurrency and asset tokenization foc ...

– Data to be featured in two oral presentations on December 8, 2025 – – Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate use – SAN DIEGO and TOKYO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced that results from the KOMET-007 combination trial of ziftomenib, a once-daily, oral investigational menin inhibitor, will be featured in two oral p ...

Funding and operational initiatives are intended to strengthen balance sheet and focus on high-growth prioritiesVANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) (“VERSES” or the “Company”), a cognitive computing company pioneering next-generation agentic software systems, is pleased to announce that it has arranged a private placement with certain institutional investors (the “Private Placement”). Under the terms of the Private Placement, VERSES will ...

业务合并交易核心信息 - Marine Thinking Inc 与特殊目的收购公司Eureka Acquisition Corp达成最终业务合并协议 合并后公司将在纳斯达克上市 交易潜在前期估值约为1.3亿美元 [1] - 交易完成后 合并公司将更名为Marine Thinking Holdings Inc 并以股票作为对价支付给Marine Thinking股东 [5] - 交易已获双方董事会一致批准 尚需满足包括监管机构和股东批准在内的惯例成交条件 [3][6] 公司业务与技术定位 - Marine Thinking是一家专注于海洋产业的实体AI技术公司 通过低成本、易组装的自主船舶导航技术 将现有造船商转型为自主船舶制造商 [2] - 公司技术旨在普及无人渡轮、内河货运、水域调查、救援及国防应用 以解决海员日益短缺的实际问题 [2] - 经过八年发展 公司已成为加拿大领先的自主船舶及船队解决方案提供商 并承接了多个加拿大联邦政府机构的创新研发项目 [2] 公司发展历程与市场应用 - Marine Thinking的技术成果已开始应用于民用领域 其自主解决方案在超过十几个国家的多个海洋产业领域得到应用 [2] - 公司创始人强调了加拿大联邦政府及哈利法克斯合作伙伴在八年创新过程中的长期孵化与支持 [4] - 基石投资者表达了对团队愿景及AI驱动海洋解决方案发展势头的信心 并对未来增长能力抱有强烈信心 [4] 交易相关方与信息渠道 - Eureka董事长兼CEO认为此次合作将加速海洋技术创新 为水产养殖、环境管理等领域带来进步 并为利益相关者创造价值 [4] - 交易的法律顾问团队包括为Eureka服务的DLA Piper律所 以及为Marine Thinking服务的Loeb & Loeb LLP和Kuo Securities Law [8] - 有关交易的详细信息将在Eureka向美国证券交易委员会提交的8-K表格和S-4注册声明中提供 [7][11]

CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ~30% CRc rate observed at clinically active target doses; initial dose escalation results in 40 patients indicate a manageable safety profile across all doses assessed Company to host in-person event on Monday, December 8, 2025, at 8:00 p.m. ET CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nas ...

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 8, 2025, at 7:00 a.m. ET during the 67th American Society of Hematology (ASH) Annual Meeting. Members of the Syndax management team will be joined by multiple key opinion leaders to discuss data updates from the Company’s Revu ...

公司核心产品数据展示 - Syndax Pharmaceuticals宣布其两款核心产品Revuforj (revumenib)和Niktimvo (axatilimab-csfr)共有23篇摘要被第67届美国血液学会(ASH)年会接受，其中包括6场口头报告[1] - 被接受的摘要包括12篇关于revumenib和11篇关于axatilimab的研究，凸显了公司在menin抑制和CSF-1R抑制领域的领导地位[1] - 公司将于2025年12月8日东部时间上午7:00在ASH年会期间举办投资者活动，并通过网络直播讨论关键数据[2] Revumenib临床研究进展 - revumenib摘要展示了在复发/难治性、一线治疗和造血干细胞移植后设置中多种急性白血病亚型的令人信服的结果[1] - 一项口头报告将重点介绍SAVE试验2期队列的结果，该试验针对新诊断的NPM1突变、KMT2A重排或NUP98重排急性髓系白血病患者，联合使用revumenib、venetoclax和decitabine/cedazuridine[5] - 另一项口头报告将报告关键AUGMENT-101试验2期部分中复发/难治性KMT2A重排急性白血病患者按白血病类型的疗效和安全性[5] - 海报展示将重点介绍revumenib在临床试验环境之外的首次真实世界经验，包括在KMT2A重排、NPM1突变或NUP98重排急性白血病患者中的应用[5] - 两项海报展示将报告revumenib联合强化化疗在新诊断NPM1突变、KMT2A重排或NUP98重排AML患者中的1期试验初步结果[5] - 一项海报展示将重点介绍对接受revumenib作为造血干细胞移植后维持治疗的儿科患者的回顾性研究结果[5] Axatilimab临床研究进展 - axatilimab摘要强调了在复发/难治性慢性移植物抗宿主病中长期获益的潜力以及在新诊断慢性移植物抗宿主病中与ruxolitinib联合使用的耐受性[1] - 一项口头报告将描述在关键2期AGAVE-201试验中，从axatilimab的FDA批准剂量(0.3 mg/kg每2周)转换为0.6 mg/kg每4周给药的复发或难治性慢性移植物抗宿主病患者中观察到的安全性和可行性[4] - 一项海报展示将重点介绍在关键2期AGAVE-201试验中复发或难治性慢性移植物抗宿主病患者axatilimab的长期治疗持续时间和安全性[8] - 另一项海报展示将报告axatilimab联合ruxolitinib在新诊断慢性移植物抗宿主病患者中的2期试验的中期安全性分析[8] 产品背景与监管地位 - Revuforj (revumenib)是一种口服、首创的menin抑制剂，获得FDA批准用于治疗伴有KMT2A易位的复发或难治性急性白血病，以及伴有NPM1突变且无满意替代治疗选择的复发或难治性急性髓系白血病[12] - revumenib此前已获得美国FDA授予的用于治疗AML、ALL和急性谱系不明白血病的孤儿药认定，以及用于治疗成人及儿科复发/难治性急性白血病患者的快速通道资格和突破性疗法认定[14] - Niktimvo (axatilimab-csfr)是一种首创的CSF-1R阻断抗体，在美国获批用于治疗至少两种全身治疗失败后的慢性移植物抗宿主病[15] - 公司于2016年从UCB获得axatilimab的全球独家权利，并于2021年9月与Incyte达成全球共同开发和商业化许可协议[16] 研发管线扩展 - 公司正在慢性移植物抗宿主病的一线联合试验中研究axatilimab，包括与ruxolitinib的2期联合试验和与类固醇的3期联合试验正在进行中[17] - axatilimab还在一项针对特发性肺纤维化患者的持续2期试验中进行研究[17] - 多项revumenib试验正在或计划在整个治疗领域进行，包括在新诊断的NPM1突变或KMT2A重排AML患者中与标准护理疗法联合使用[13]